focus -WSS

focus

author：fashion 2025-08-19 15:02:09 - browse：1

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Oral obesity drug from Viking Therapeutics hits key early target

knowledge

Wikipedia

WSS

Maui funeral service workers on devastation of fires: 'I'm in shock'

Some of the ways extreme heat will change life as we know it

Trial using CRISPR to edit HIV out of cells disappoints

Study: Black kids more likely to die after surgery than white kids

Harvard scientists, with Google, unveil the most detailed brain map ever

Scientific mystery highlights the blind spots in genomics databases

hotspot

focus

knowledge

ChatGPT in medicine: STAT answers readers' burning questions

People with mental disorders often marry others with same

Medicare proposal to cover medical devices draws a mixed reaction

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Apple is now the first public company to be valued at $3 trillion

Study: Black kids more likely to die after surgery than white kids

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Hundreds died while taking an arthritis drug, but nobody alerted patients

Novavax promises a turnaround & Lilly roils the obesity market

Researchers test human milk's ability to repair gut microbiome

explore

Republican states more likely to report Covid vaccine side effects

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Target recalls 2.2 million additional candles due to laceration, burn hazards

Trial using CRISPR to edit HIV out of cells disappoints

Overprescribed: High cost isn't America's only drug problem

White House drug shortages task force keeps mum with Congress

entertainment

knowledge

Wikipedia

knowledge